Zylox-Tonbridge 2024 Investor Open Day Successfully Held in Hangzhou

On November 28, Zylox-Tonbridge ("2190.HK", hereinafter referred to as "the Company") successfully hosted its 2024 Investor Open Day in Hangzhou, China. The event attracted more than 200 participants, including investors and securities analysts, both online and offline. Attendees were provided with an in-depth experience of the Company's extensive product portfolio and its latest R&D achievements. The Company's leadership team also shared their insights and perspectives on the challenges and opportunities facing China's medical device markets as well as the current status and development trends of the global industry.

Comprehensive and Innovative Product Portfolio on Display

At the Zylox-Tonbridge Product Exhibition Center, the Company showcased a range of domestic and internationally approved products, including the latest launched innovative products such as the ZYLOX Penguin Venous Stent System, Kylin Flow Diverter and ZYLOX Unicorn® Vascular Suture-mediated Closure System. Investors engaged deeply with the showcased products, discussing R&D technologies and manufacturing management with the Company's scientists and engineers.

Additionally, the Company presents two disruptive devices under development in collaboration with Avinger, a medical device company developing intra-vascular image-guided, catheter-based systems for diagnosing and treating vascular disease. The two product candidates are the ZYLOX Pantheris Atherectomy Catheter and the ZYLOX Tigereye ST CTO-Crossing catheter, which are the first and only to integrate atherectomy or CTO crossing functions with real-time intravascular OCT imaging. Both product candidates recently were granted as innovative medical devices by NMPA. 

As of June 2024, Zylox-Tonbridge has obtained NMPA approval for 44 products and secured regulatory approvals for 12 products in overseas markets, covering regions including Europe, South America, and the Middle East.

Exploring Industry Opportunities and Global Prospects

Following the product showcasing, Zylox-Tonbridge's leadership team presented the Company's long-term strategies, research and development progress, and sustainable competitive advantages in commercialization. 

Dr. Jonathon Zhao, Chairman and CEO of Zylox-Tonbridge, emphasized that the Company will commit itself to achieving sustainable growth by leveraging the opportunities of healthcare reform, innovative product strategies, and overseas business initiatives. He noted that the Company had gained a net profit during the the first half of this year. This milestone highlights the Company's ability to achieve sustainable growth. “Looking forward, Zylox-Tonbridge will continue to improve operational efficiency and provide patients with high-quality products to solidify our leadership in the market.”Dr. Jonathon ZHAO said.

In the panel session, the Company’s Sales and Marketing team engaged with healthcare policy experts and business partners to discuss the opportunities and challenges of healthcare reform for domestic medical device companies.

During the Q&A session, Dr. Jonathon ZHAO and the leadership team addressed a wide range of questions from investors, focusing on key topics such as the Company’s 2025 business outlook, international expansion strategies, product pipeline innovation, and industry developments.

The 2024 Investor Open Day concluded successfully with vibrant discussions and enthusiastic participation. Looking ahead, Zylox-Tonbridge will continue to uphold its commitment to "Innovation for Quality Life," delivering high-quality, affordable medical devices to patients worldwide and driving technological advancement and sustainable development in the vascular interventional medical device industry.